# EDGAR Filing Document

**Accession Number:** 0001799883
**File Stem:** 0001085146-25-005687
**Filing Date:** 2025-8
**Character Count:** 16874
**Document Hash:** 544b2e70ffe086575b04f78002506c62
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001085146-25-005687.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001085146-25-005687

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250829

**EFFECTIVENESS DATE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 5AM Venture Management, LLC
- **CENTRAL INDEX KEY:** 0001799883

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-19757
- **FILM NUMBER:** 251281241

**BUSINESS ADDRESS:**
- **STREET 1:** 4 EMBARCADERO CENTER, SUITE 3110
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
- **BUSINESS PHONE:** (415) 993-8565

**MAIL ADDRESS:**
- **STREET 1:** 4 EMBARCADERO CENTER, SUITE 3110
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001799883

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** 5AM Venture Management, LLC

**Address:** 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO, CA 94111

**Telephone number:** 415-993-8570

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-19757

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                   | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                                                                                            | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Adverum Biotechnologies, Inc.    | 00773U207 | 06/17/2025     | To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement.                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |         541666 |                0 | FOR         |                                   541666 | FOR                         |  |
| Alector, Inc.                    | 014442107 | 06/11/2025     | Advisory vote on executive compensation.                                                                                                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |         995841 |                0 | FOR         |                                   995841 | FOR                         |  |
| AnaptysBio, Inc.                 | 032724106 | 06/17/2025     | To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         357733 |                0 | FOR         |                                   357733 | FOR                         |  |
| AnaptysBio, Inc.                 | 032724106 | 06/17/2025     | Non-binding advisory vote on the frequency of holding future advisory votes regarding named executive officer compensation.                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |         357733 |                0 | 1 YEAR      |                                   357733 | FOR                         |  |
| Biohaven Ltd.                    | G1110E107 | 05/05/2025     | A non-binding advisory vote on the compensation of the Company's named executive officers.                                                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         478972 |                0 | FOR         |                                   478972 | FOR                         |  |
| Celldex Therapeutics, Inc.       | 15117B202 | 06/05/2025     | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |         497270 |                0 | FOR         |                                   497270 | FOR                         |  |
| Cidara Therapeutics, Inc.        | 171757206 | 07/18/2024     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |          56725 |                0 | FOR         |                                    56725 | FOR                         |  |
| Cidara Therapeutics, Inc.        | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |          56725 |                0 | FOR         |                                    56725 | FOR                         |  |
| Dianthus Therapeutics, Inc.      | 252828108 | 05/22/2025     | To approve, on an advisory basis, the compensation paid to our named executive officers.                                                                                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |        1027711 |                0 | FOR         |                                  1027711 | FOR                         |  |
| EyePoint Pharmaceuticals, Inc.   | 30233G209 | 06/18/2025     | To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |        1050000 |                0 | FOR         |                                  1050000 | FOR                         |  |
| EyePoint Pharmaceuticals, Inc.   | 30233G209 | 06/18/2025     | To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |        1050000 |                0 | 1 YEAR      |                                  1050000 | FOR                         |  |
| Mersana Therapeutics, Inc.       | 59045L106 | 06/12/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        1305000 |                0 | FOR         |                                  1305000 | FOR                         |  |
| MoonLake Immunotherapeutics      | 61559X104 | 06/05/2025     | Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         282313 |                0 | FOR         |                                   282313 | FOR                         |  |
| Praxis Precision Medicines, Inc. | 74006W207 | 06/26/2025     | To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. | SECTION 14A SAY-ON-PAY VOTES |         170000 |                0 | FOR         |                                   170000 | FOR                         |  |
| Protara Therapeutics, Inc.       | 74365U107 | 06/11/2025     | Approval, on an advisory basis, of the compensation of Protara Therapeutics, Inc.'s named executive officers, as disclosed in the proxy statement                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |         800000 |                0 | FOR         |                                   800000 | FOR                         |  |
| scPharmaceuticals Inc.           | 810648105 | 06/03/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |        1200647 |                0 | FOR         |                                  1200647 | FOR                         |  |
| Silence Therapeutics plc         | 82686Q101 | 06/26/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the attached proxy                                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         476200 |                0 | FOR         |                                   476200 | FOR                         |  |
| Silence Therapeutics plc         | 82686Q101 | 06/26/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers                                                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |         476200 |                0 | 1 YEAR      |                                   476200 | FOR                         |  |
| Skye Bioscience, Inc.            | 83086J200 | 06/06/2025     | Consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                                                                                                | SECTION 14A SAY-ON-PAY VOTES |        8167206 |                0 | FOR         |                                  8167206 | FOR                         |  |
| Skye Bioscience, Inc.            | 83086J200 | 06/06/2025     | Consider and vote upon, on an advisory basis, whether the stockholder vote to approve the compensation of the named executive officers as required by Section 14A(a)(2) of the Securities Exchange Act of 1934, as amended, should occur every one, two or three years.                                                     | SECTION 14A SAY-ON-PAY VOTES |        8167206 |                0 | 1 YEAR      |                                  8167206 | FOR                         |  |
| Tectonic Therapeutic, Inc.       | 878972108 | 06/06/2025     | Advisory approval of the compensation of the Company's Named Executive Officers.                                                                                                                                                                                                                                            | SECTION 14A SAY-ON-PAY VOTES |         511660 |                0 | FOR         |                                   511660 | FOR                         |  |
| Tectonic Therapeutic, Inc.       | 878972108 | 06/06/2025     | Advisory vote on the frequency of stockholder advisory votes on executive compensation.                                                                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |         511660 |                0 | 1 YEAR      |                                   511660 | FOR                         |  |
| Viking Therapeutics, Inc.        | 92686J106 | 05/20/2025     | To Approve, On An Advisory Basis, The Compensation Of Our Named Executive Officers.                                                                                                                                                                                                                                         | SECTION 14A SAY-ON-PAY VOTES |         189593 |                0 | FOR         |                                   189593 | FOR                         |  |
| Viridian Therapeutics, Inc.      | 92790C104 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |         736595 |                0 | FOR         |                                   736595 | FOR                         |  |
| Zentalis Pharmaceuticals, Inc.   | 98943L107 | 06/17/2025     | To approve, on an advisory (non-binding) basis, the compensation of our named executive officers.                                                                                                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |         490000 |                0 | FOR         |                                   490000 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** 5AM Venture Management, LLC

**By (Signature):** Lauren A. Daniel

**By (Printed Signature):** Lauren A. Daniel

**By (Title):** Chief Compliance Officer  Deputy General Counsel

**Date:** 08/29/2025